Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00578461 · ClinicalTrials.gov registry record · NA

T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE

A NA study, sponsored by Baylor College of Medicine.

Terminated
Registry status
NA
Development phase
26
Enrollment target

NCT00578461: Clinical Trial NA study, sponsored by Baylor College of Medicine.

NCT00578461 is a NA study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00578461, a NA study, was terminated before completion, sponsored by Baylor College of Medicine.

TERMINATED
Registry status
NA
Development phase
26 participants
Enrollment target

Study Summary

Patients are being asked to participate in this study because they have a cancer in their blood (such as leukemia or lymphoma) or myelodysplastic/myeloproliferative (pre-leukemia). We suggest a treatment that might help them live longer without disease than other treatment plans would. This treatment is known as a stem cell transplant. We believe this may help the patient as it allows us to give much stronger doses of drugs and radiation to kill the diseased cells than we could give without the transplant. We also think that the healthy cells may help fight any diseased cells left after the transplant. Stem Cells are special "mother" cells that are found in the bone marrow (the spongy tissue inside bones), although some are also found in the bloodstream (peripheral blood). As they grow, they become either white blood cells which fight infection, red blood cells which carry oxygen and remove waste products from the organs and tissues or platelets, which enable the blood to clot. For the transplant to take place, we will collect these stem cells from a "donor" (a person who agrees to donate these cells) and give them to the patient. The patient has a type of blood cell cancer or other blood problem that is very hard to cure with standard treatments and they will receive a stem cell transplant (SCT). If they have a brother or sister that is a perfect match and agrees to donate, the stem cells will come from him/her. Before the transplant, two very strong drugs plus total body irradiation will be given to the patient (pre-conditioning). This treatment will kill most of the blood-forming cells in the bone marrow. We will then give the patient the healthy stem cells. Once these healthy stem cells are in the bloodstream they will move to the bone marrow (graft) and begin producing blood cells that will eventually mature into healthy red blood cells, white blood cells and platelets. Also, we will ask permission to draw blood from the patient so that we can measure the num

Primary Outcome

The investigative intent is to determine the changes in numbers and function of the regulatory cell population using the best methods to measure this cell population. The frequency of T cells will be summarized at baseline and each time point of follow-up.

Interventions

  • DRUG Cyclophosphamide
  • DRUG Mesna
  • DRUG Ara C
  • RADIATION TBI-Total Body Irradiation

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2007-10
Est. Completion 2013-05
Phase NA
Baylor College of Medicine

616 total trials

Why NCT00578461 stopped before completion

NCT00578461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT00578461 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00578461 about?

NCT00578461 is a clinical study titled "T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE". Patients are being asked to participate in this study because they have a cancer in their blood (such as leukemia or lymphoma) or myelodysplastic/myeloproliferative (pre-leukemia). We suggest a treatment that might help them live longer without disease than other treatment plans would. This treatmen...

What is the current status of trial NCT00578461?

This trial is currently terminated. It is a NA study. The enrollment target is 26 participants. The study started on 2007-10. Estimated completion is 2013-05.

What interventions are being tested in trial NCT00578461?

The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), Ara C (DRUG), TBI-Total Body Irradiation (RADIATION).

Who is sponsoring clinical trial NCT00578461?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00578461's enrollment target sits among peer trials

26 1710th of 2000 higher than 289 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00578461, the US trial registry maintained by the National Library of Medicine. NCT00578461 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.